Carbidopa, a drug in use for management of Parkinson disease inhibits T cell activation and autoimmunity.

Carbidopa, a drug in use for management of Parkinson disease inhibits T cell activation and autoimmunity.

Carbidopa is a drug that blocks conversion of levodopa to dopamine outside of central nervous system (CNS) and thus inhibits unwanted side effects of levodopa on organs located outside of CNS during management of Parkinson's Disease (PD). PD is associated with increased expression of inflammato...

Full description

Bibliographic Details
Main Authors: Huabin Zhu, Henrique Lemos, Brinda Bhatt, Bianca N Islam, Abhijit Singh, Ashish Gurav, Lei Huang, Darren D Browning, Andrew Mellor, Sadanand Fulzele, Nagendra Singh
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5595290?pdf=render

Internet

http://europepmc.org/articles/PMC5595290?pdf=render

Similar Items